Aadi Bioscience, INC Form 4 insider transactions
Director Richard E. Maroun acquired stock options in Aadi Bioscience, Inc. on June 12, 2024.
Director Mohammad Hirmand acquired stock options for 45,832 shares of Aadi Bioscience, Inc. on June 12, 2024.
Director Emma Reeve reports the acquisition of stock options in Aadi Bioscience, Inc.
Director Caley Castelein of Aadi Bioscience, Inc. acquired stock options for 45,832 shares on June 12, 2024.
Anupam Dalal, a director of Aadi Bioscience, acquired stock options for 45,832 shares on June 12, 2024.
Director Karin M. Hehenberger acquired stock options in Aadi Bioscience, Inc. on June 12, 2024.
Neil Desai, Executive Chairman of Aadi Bioscience, sold shares of the company's common stock on June 3rd and 4th, 2024, according to a Form 4 filing with the SEC.
Neil Desai, Executive Chairman of Aadi Bioscience, Inc., sold 40,000 shares of common stock at an average price of $1.9296 on May 1, 2024, according to a Form 4 filing with the SEC.
Neil Desai, Executive Chairman of Aadi Bioscience, sold shares of common stock on April 1st and 2nd, 2024, according to a Form 4 filing with the SEC.
Neil Desai, Executive Chairman of Aadi Bioscience, sold shares of the company's common stock on March 1 and March 4, 2024, according to a Form 4 filing with the SEC.
Loretta M. Itri, Chief Medical Officer of Aadi Bioscience, Inc., reports the acquisition of stock options and restricted stock units as part of her compensation.
A Form 4 filing reveals that Aadi Bioscience CEO David James Lennon acquired stock options and restricted stock units (RSUs) on March 1, 2024, related to his compensation and continued service with the company.
A Form 4 filing reveals that Aadi Bioscience's CFO, Scott M. Giacobello, was granted stock options and restricted stock units on March 1, 2024.